Become an Early Access tester for ioHepatocytes (Discovery Research)

Facilitate longitudinal studies of liver disease and drug responses in 2D culture using consistent, functional human iPSC-derived hepatocytes.

Register for our Early Access Program now!

Only ioHepatocytes (Discovery Research)
provide a source of human iPSC-derived hepatocytes that show:

Long-lasting function in 2D

Cells exhibit sustained albumin secretion and mature phenotype for over two weeks, offering a functional model for long-term liver studies.

Expected hepatocyte function

Recapitulate key human hepatocyte functions, including bile canaliculi-like structure formation, lipid accumulation, urea production, and glycogen storage, providing you with a well-characterised tool for liver research.

Batch-to-batch consistency

Bulk RNA-sequencing demonstrates unparalleled consistency between 3 independently generated batches, so you can trust every vial to deliver reproducible results no matter when you perform your assay.

Consistent, functional human iPSC-derived hepatocytes to enhance in vitro liver models

ioHepatocytes (Discovery Research), powered by opti-ox deterministic cell programming, deliver built-in batch-to-batch consistency for reproducible data. These highly characterised hepatocytes display a cobblestone morphology, prominent nuclei and expression of core hepatocyte markers from day 4.

The cells maintain mature functionality in 2D for over two weeks, supporting long-term studies of metabolic diseases and slow-acting compounds. With key liver functions, including albumin and urea secretion and cytochrome P450 activity, and culture stability beyond three weeks, they provide a reliable, reproducible model for drug metabolism, toxicity, and disease research.

Register for Early Access

ioHepatocytes_Discovery_Research_D14_morphology

Become an Early Access tester

Be the first to experience the next generation of human in-vitro hepatocyte models. We are offering a Early Access evaluation pack providing 3 vials for $995 / £995 / €995 on your first order.

This Early Access Program is a chance to evaluate:

Cell handling and protocol robustness
Morphology and marker expression
Functional performance

Limited spaces available.

Register for Early Access

bitbio-bundles-iocells_eval-header-mobile

ioHepatocytes (Discovery Research)

Highly characterised, consistent and functional

ioHepatocytes_Discovery_Research_ICC_Panel-2

Rest assured.
We know our cells.

Our deterministically programmed cells are highly defined, proven by ICC, RT-qPCR, RNA sequencing, and functional assays, so you always know exactly what is in every vial.

ioHepatocytes (Discovery Research) express core pan-hepatocyte markers from as early as 4 days post-thaw. Immunofluorescence staining shows homogenous expression of Albumin and HNF4a at day 14 post-thaw (pictured above).

ioHepatocytes_Discovery_Research_consistency

Consistent.
And made to stay that way.

ioHepatocytes (Discovery Research) are powered by opti-ox, meaning they have consistency built-in.

Bulk RNA-sequencing data from three independent batches at five different time points throughout the programming protocol shows high consistency between each batch.

ioHepatocytes_Discovery_Research_albumin_secretion-1

Functional.
Demonstrable functionality over time.

Hepatocytes are the main cells in the body that produce albumin, its secretion is a primary marker of liver function and health

At day 4 post-thaw ioHepatocytes (Discovery Research) are secreting around 5,000 ng Albumin per million cells. As cells continue to mature, so does their metabolic competency. With secretion measured at >50,000 to >80,000 ng from day 10 - 14 post-thaw

20 minutes with our scientist:

ioHepatocyte data explained

Become an Early Access tester for
ioHepatocytes (Discovery Research)

Get in touch to learn more about our Early Access Program and transform your in vitro liver modelling workflows. Limited spaces and availability.